Welcome to Gaebler Lab for Translational Immunology of Viral Infections
What We Do
Welcome to the Gaebler Laboratory for Translational Immunology of Viral Infections at Charité Universitätsmedizin Berlin. Our team is dedicated to studying immune responses to viral infections, with a particular focus on HIV. Our goal is to advance research that prioritizes patient needs, enhancing our understanding of how viral infections work and developing effective treatments that improve medical care. Located in Berlin within Germany's only independent Department of Infectious Diseases, we are at the forefront of innovative research focused on finding an HIV cure, advancing HIV cure research at Charité Berlin, and furthering the field of viral immunology.
photos by Jens Gyarmaty
News and Updates
Stay tuned for future events and updates!
Our Team
From left to right: Christian Gaebler, Naomi Perkins, Han Le, Tomer Einav, Vanessa Igbokwe, Rachel Scheck, Michela Perotti, Sabine Weickmann, Franziska Huf
Christian Gaebler -
Christian Gaebler is a Professor at Charité Universitätsmedizin Berlin, leading the Laboratory for Translational Immunology of Viral Infections and the Personalized Infectious Medicine program at the Berlin Institute of Health. Previously, he was an Assistant Professor at Rockefeller University in New York. As a physician-scientist, his research ranges from basic immunology of viral infections to the clinical development of antibody immunotherapies for infectious diseases, focusing on HIV. Christian’s contributions have earned him significant recognition, including the 2021 Top 10 Clinical Research Achievement Award and the 2023 German AIDS Award from the German AIDS Society.
KOHIVI - HIV Persistence & Immune Response
This study follows individuals living with HIV over an extended period to analyze the dynamic relationship between HIV persistence—how the virus remains in the body despite treatment—and the immune system’s specific responses to the virus.
SAMBA - Novel Hepatitis B Therapy
This first-in-human Phase 1 study tests the safety and antiviral effects of HepB mAb19, a new antibody treatment targeting the hepatitis B virus. It involves people with chronic hepatitis B already on standard antiviral therapy
RIO - Broadly Neutralizing Antibodies as HIV Therapy
The RIO study is a Phase II trial conducted at multiple centers around the world. It tests HIV-specific broadly neutralizing antibodies (bNAbs) to evaluate their safety and effectiveness across several groups.
Publications
Christian Gaebler's Publications on Google Scholar
https://scholar.google.com/citations?user=iNlx_jgAAAAJ&hl=en
more about our HIV Research in Berlin to follow!
Blog
Funding
HJH Stiftung
_edited.jpg){kind=logo}
